Home > WJCD>

Dr. Cornel Pater

Hospira/Pfizer (Biosimilars), Sweden

Email: drcornelpater@aol.com


2001 MPH degree, Master of Public Health - NSPH, Utrecht, the Netherlands

1998 MSc degree, Master of Science in Clinical Epidemiology and Biostatistics, Erasmus, University Rotterdam, the Netherlands

Publications (Selected)

  1. Pater C, Severin T. Management of Acute Heart Failure – Is there a Paradigm Shift around the Corner? - World Journal of Cardiovascular Diseases, 2013, 3, 1-7. doi:10.4236/wjcd.2013.32A001.
  2. Pater C. Hyperuricemia and Hypertension – A Causal relationship ignored for all too Long – Current Hypertension Reviews, Vol. 7, Number 1, Feb. 2011, pp. 41- 53(13).
  3. Pater C. Mild Cognitive Impairment (MCI) - The Novel Trend of Targeting Alzheimer's Disease in Its Early Stages - Methodological Considerations – Current Alzheimer Research - Volume 8, Number 7, November 2011 , pp. 798-807(10).
  4. Pater C. Beyond the Evidence of the New Hypertension Guidelines. Blood pressure measurement – is it good enough for accurate diagnosis of hypertension? Time might be in, for a paradigm shift (I) Pater C. The Blood Pressure "Uncertainty Range" - a pragmatic approach to overcome current diagnostic uncertainties (II) Pater C. Methodological considerations in the design of trials for safety assessment of new drugs and chemical entities. Submitted for publication to Curr Control Trials Cardiovasc Med2005, 6:1.
  5. Pater C. Current trends in the cardiovascular clinical trial arena (I) – Curr Control Trials Cardiovasc Med. 2004, 5:4.
  6. Pater C. Individualizing therapy – in search for approaches to maximize the benefit of drug treatment (II) – Curr Control Trials in Cardiovasc Med.2004, 5:7.
  7. Pater C. Equivalence and noninferiority trials – are they viable alternatives for registration of new drugs? (III) – Curr Control Trials in Cardiovasc Med. 2004, 5:8.
  8. Pater C, Bhatnagar D, Berrou JP, Luszick J, Beckmann K. A novel approach to treatment of hypertension in diabetic patients - A multicenter, double-blind, randomized study comparing the efficacy of combination therapy of Eprosartan versus Ramipril with low-dose Hydrochlorothiazide and Moxonidine on blood pressure levels in patients with hypertension and associated diabetes mellitus type 2 – rationale and design. (ASTRID – Antihypertensive treatment of Systolic/diastolic hypertension comparing Teveten with Ramipril in type 2 Diabetics) – CurrControl Trials in Cardiovasc Med 2004, 5:9.
  9. Pater C, Compagnone D, Luszick J, Verboom CN. Effect of Omacor on HRV parameters in patients with recent uncomplicated myocardial infarction – A randomized, parallel group, double-blind, placebo-controlled trial: study design [ISRCTN75358739]. Curr Control Trials in Cardiovasc Med 2003 Oct 15, 4:2.
  10. Pater C. The current status or primary prevention in coronary heart disease. Curr Control Trials in Cardiovasc Med 2001, 2:24-37.
  11. Pater C, Jacobsen CD, Rollag A, Sandvik L, Erikssen J, Karin Kogstad E. Design of a randomized controlled trial of comprehensive rehabilitation in patients with myocardial infarction, stabilized acute coronary syndrome, percutaneous transluminal coronary angioplasty or coronary artery bypass grafting: A Comprehensive Cardiac Rehabilititation Trial (the CORE Study).Curr Control Trials in Cardiovasc Med 2000, 1:177-183.